Ol'Ga Dmitrievna Ostroumova

Ol'Ga Dmitrievna Ostroumova

Auto-generated profile, based on publicly available information

Ol'Ga Dmitrievna Ostroumova

Russian Medical Academy of Continuous Professional Education

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2021 in Experimental and Clinical Gastroenterology
Verified
Journal Article
Open access
PDF file
LLL. B. Lazebnik
L. B. Lazebnik
EGE. V. Golovanova
E. V. Golovanova
STS. V. Turkina
S. V. Turkina
KRK. L. Raikhelson
K. L. Raikhelson
SOS. V. Okovityy
S. V. Okovityy
ЮУЮ. П. Успенский
Ю. П. Успенский
Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия

14 February 2021 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
IDI. I. Dedov
I. I. Dedov
MSMarina Shestakova
Marina Shestakova
GMG. A. Melnichenko
G. A. Melnichenko
NMN. V. Mazurina
N. V. Mazurina
EAE. N. Andreeva
E. N. Andreeva
МХМ. Б. Хамошина
М. Б. Хамошина
МЕЖДИСЦИПЛИНАРНЫЕ КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ «ЛЕЧЕНИЕ ОЖИРЕНИЯ И КОМОРБИДНЫХ ЗАБОЛЕВАНИЙ»

21 December 2018 in Russian Journal of Cardiology
Verified
Journal Article
Open access
ZKZh. D. Kobalava
Zh. D. Kobalava
AKA. O. Konradi
A. O. Konradi
SNS. V. Nedogoda
S. V. Nedogoda
GAG. P. Arutyunov
G. P. Arutyunov
EBElena Baranova
Elena Baranova
GCGalina Chumakova
Galina Chumakova
Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов/Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018г

8 August 2020 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OTO. N. Tkacheva
O. N. Tkacheva
NVN. M. Vorob’eVa
N. M. Vorob’eVa
YKYu. V. Kotovskaya
Yu. V. Kotovskaya
OOO. D. Ostroumova
O. D. Ostroumova
MCMarina S. Cherniaeva
Marina S. Cherniaeva
ЮКЮ. В. Котовская
Ю. В. Котовская
Aim. To study the prevalence of geriatric syndromes and assess their relationship with senile asthenia in persons aged ³65 years living in Russian regions with different demographic, climatic and socio-economic characteristics. Material and methods. We examined 664 patients aged 65-107 years (mean age, 79±9 years; men, 25%) living in Moscow (n=365) and Voronezh (n=299). All patients underwent a comprehensive geriatric examination, which consisted of two stages: a survey with original questionnaire and an objective examination. Results. The prevalence of senile asthenia was 66,4%, including 47,4% in people aged 65-74, 71,1% — 75-84 years, and 82,8% — ³85 years (p for trend <0,001). Senile asthenia was associated with age (odds ratio (OR), 2,36; 95% confidence interval (CI), 1,89-2,93; p<0,001) and female sex (OR, 1,52; 95% CI 1,06-2,18; p=0,024). Patients with senile asthenia had a lower socioeconomic status. Also, close associations of senile asthenia with other geriatric syndromes (dementia, depression, vision and hearing impairment, incontinence, falls, high risk of falls, functional decline, failure to thrive) with OR from 1,32 to 7,22 were revealed. Conclusion. The first results of the EVCALIPT study indicate a high incidence of senile asthenia in persons aged ³65 years and its close association with other geriatric syndromes and socio-economic factors.

28 September 2018 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
OOOlga Ostroumova
Olga Ostroumova
ESElena Surkova
Elena Surkova
ECEvgenia Chikh
Evgenia Chikh
RERebrova Ekaterina
Rebrova Ekaterina
MBMiron Borisov
Miron Borisov
In recent years, a large amount of data has been accumulated on the relationship between cognitive impairment, dementia and diabetes mellitus. This article presents an overview of modern literature, including the definition of cognitive functions, the modern classification of cognitive impairment, pathogenetic mechanisms of diabetes mellitus influence on the development of cognitive impairment and dementia (neurogenesis, integrity of the blood-brain barrier, systemic inflammatory reactions, hyper- and hypoglycemia, insulin resistance, vascular dysfunction of the microvasculature and increase in glucocorticosteroids). The influence of anti-diabetic medications on cognitive functions has been examined in detail: insulin preparations, oral hypoglycemic agents of the biguanide group (metformin), thiazolidinediones (rosiglitazone and pioglitazone), sulfonylurea derivatives (glycazide, glipizide), a-glucosidase (acarbose) inhibitors, incretin-directed therapy (receptor agonists glucan-like peptide (exenatide and liraglutide) and inhibitors of dipeptidylpeptidase type 4 (sitagliptin, vildagliptin and alogliptin)), sodium glucose inhibitors cotransporter type 2. The data demonstrating a multidirectional effect on the cognitive functions of various antidiabetic drugs is presented, the possible influence on the rate of progression of cognitive impairment and the risk of dementia of intensive control of plasma glucose level in comparison with the standard decrease in patients with type 2 diabetes is analyzed.

24 February 2024 in Cardiovascular Therapy and Prevention
Verified
Journal Article
Open access
PDF file
ODOxana M. Drapkina
Oxana M. Drapkina
VMV. I. Mazurov
V. I. Mazurov
AMA. I. Martynov
A. I. Martynov
ENE. L. Nasonov
E. L. Nasonov
SSS. A. Saiganov
S. A. Saiganov
ЮХЮ. Ш. Халимов
Ю. Ш. Халимов
Консенсус для врачей по ведению пациентов с бессимптомной гиперурикемией в общетерапевтической практике